Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Unique features and clinical importance of acute alloreactive immune responses
Charlotte F. Inman, … , Ram Malladi, Paul Moss
Charlotte F. Inman, … , Ram Malladi, Paul Moss
Published May 17, 2018
Citation Information: JCI Insight. 2018;3(10):e97219. https://doi.org/10.1172/jci.insight.97219.
View: Text | PDF
Research Article Hematology Immunology

Unique features and clinical importance of acute alloreactive immune responses

  • Text
  • PDF
Abstract

Allogeneic stem cell transplantation (allo-SCT) can cure some patients with hematopoietic malignancy, but this relies on the development of a donor T cell alloreactive immune response. T cell activity in the first 2 weeks after allo-SCT is crucial in determining outcome, despite the clinical effects of the early alloreactive immune response often not appearing until later. However, the effect of the allogeneic environment on T cells is difficult to study at this time point due to the effects of profound lymphopenia. We approached this problem by comparing T cells at week 2 after allograft to T cells from autograft patients. Allograft T cells were present in small numbers but displayed intense proliferation with spontaneous cytokine production. Oligoclonal expansions at week 2 came to represent a substantial fraction of the established T cell pool and were recruited into tissues affected by graft-versus-host disease. Transcriptional analysis uncovered a range of potential targets for immune manipulation, including OX40L, TWEAK, and CD70. These findings reveal that recognition of alloantigen drives naive T cells toward a unique phenotype. Moreover, they demonstrate that early clonal T cell responses are recruited to sites of subsequent tissue damage and provide a range of targets for potential therapeutic immunomodulation.

Authors

Charlotte F. Inman, Suzy A. Eldershaw, Joanne E. Croudace, Nathaniel J. Davies, Archana Sharma-Oates, Tanuja Rai, Hayden Pearce, Mirjana Sirovica, Y.L. Tracey Chan, Kriti Verma, Jianmin Zuo, Sandeep Nagra, Francesca Kinsella, Jane Nunnick, Rasoul Amel-Kashipaz, Charles Craddock, Ram Malladi, Paul Moss

×

Figure 2

Week 2 T cell clones are implicated in the AIR, persist throughout the period immediately after transplant, and are detectable in GvHD-affected tissues.

Options: View larger image (or click on image) Download as PowerPoint
Week 2 T cell clones are implicated in the AIR, persist throughout the p...
(A) An example of TCRVβ usage by T cells within the stem cell product (SCP; [top left]) and at week 2 (bottom left) after SCT from an allograft patient. Individual TCRVβ families are shown on the x axis; the y axis shows the percentage of total T cells expressing each individual TCRVβ family. The ratio of SCP and week 2 TCRVβ usage in patients who received autografts, received allografts and did not develop GvHD, and received allografts and did go on to develop GvHD is also shown. The number of TCRVβ families detected at week 2 is represented as a percentage of the number detected within the SCP in paired samples from individual patients. Data were analyzed by 2-tailed, Mann-Whitney U test, comparing No GvHD with GvHD and No GvHD with Auto, **P < 0.01. (B) Donut charts showing the percentage of the total T cell repertoire at 2 months after and 4–5 months after allo-SCT in 4 patients (left to right) that is attributable to clones identified at week 2 (shown as percentages in the centre of the donuts). Dark green shading represents clones not detectable at week 2. (C) H&E-stained section (original magnification, ×60) of liver from a liver aGvHD patient, showing infiltration of bile duct epithelium by atypical lymphocytes, associated with epithelial cell degenerative changes, indicative of aGvHD (top image). A section of liver with CD3 immunostaining from the same patient at (original magnification, ×20), showing infiltration of portal tracts, including bile ducts by CD3-positive lymphocytes (bottom image). Venn diagram showing the number of shared TCRβ chain CDR3 sequences (overlap between blue and pink sets) between week 2 (blue set) and GvHD-affected liver (pink set) in the same patient. Line graph showing the log10 frequency of reads for each T cell clone present in the blood at week 2 and in the liver at the point of aGvHD in the same patient.

Copyright © 2025 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts